x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:23:42

Axitinib's Big Weekend

OncoPharm ·

2019/02/21

Axitinib studies presented at ASCO-GU '19 with simultaneous NEJM publication are discussed, followed by a brief overview (18:50) of darolutamide, a new anti-androgen, and its drug interaction potential.

en

00:15:50

IRIS

OncoPharm ·

2019/02/14

The Landmarks in Oncology Pharmacy series returns to discuss the International Randomized Study of Interferon vs. STI571 (imatinib) aka IRIS.

en

00:14:40

Cannabidiol (CBD) & Potential Drug Interactions In...

OncoPharm ·

2019/02/07

CBD use is becoming more widespread in society, including in cancer patients. Potential, and significant, drug interaction concerns should be considered.

en

00:19:08

Mucositis & Stomatitis

OncoPharm ·

2019/01/31

Mucositis & stomatitis are basically interchangeable terms for one of the hallmark chemotherapy toxicities. We discuss its pathophysiology, prevalent, and prevention/treatment.

en

00:18:06

Olaratumab, Goodbye?

OncoPharm ·

2019/01/24

Olaratumab received accelerated approval in 2016 under the condition a phase III study would confirm its benefit. It didn't. We explore some possible explanations why a seemingly promising drug for a tough disease hasn't panned out...

en

00:53:17

Conversation With An Osteosarcoma Survivor

OncoPharm ·

2019/01/17

It's always enlightening to talk to a cancer survivor and is an essential part of the patient care process. This conversation touches on chemo-induced toxicities (e.g. ifosfamide neurotoxicity), supportive care advances (olanzapine!), and the anxiety of survivors live with while living scan-to-scan. Brought to you by the Bill Gatton College of Pharmacy.

en

00:13:57

New & Niche Drugs

OncoPharm ·

2019/01/10

We finish discussing the 2018 FDA-approvals (calaspargase, ravulizumab, tazgraxofusp).

en

00:16:24

mFOLFIRINOX

OncoPharm ·

2019/01/03

New year, new chemo regimen to discuss. We go over mFOLFIRINOX for adjuvant pancreatic cancer from the recently published PRODIGE-24 study. We discuss out the regimen is modified, where to find dose reductions, and how many patients required G-CSF.

en

00:07:59

Let's Talk About Mr. Gower

OncoPharm ·

2018/12/20

Keeping it light this Holiday Season with a discussion of the portrayal of pharmacists, notably Mr. Gower from It's a Wonderful Life, in pop culture. Regular Pods return in 2019.

en

00:20:16

FOLFOX (MOSAIC Trial)

OncoPharm ·

2018/12/13

The Landmarks in Oncology Pharmacy series returns with a discussion of MOSAIC: FOLFOX adjuvant chemotherapy for stage ii & STAGE III colon cancer.

en

00:17:28

Gilteritinib

OncoPharm ·

2018/12/05

Another week, another FDA-approval for AML. We discuss the latest in #oncopharm approvals: the FLT3-inhibitor gilteritinib. For more background reading, try here: https://doi.org/10.1177%2F1078155218802620

en

00:26:50

Elderly AML & Larotrectinib

OncoPharm ·

2018/11/27

The often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication). Then, (17:30) we discuss the 2nd drug "tissue agnostic" FDA approval by delving into NTRK-fusion-gene tumors and larotrectinib.

en

00:22:05

Rise (& Fall) Of ESAs

OncoPharm ·

2018/11/21

Describing the rationale for and rise in widespread ESA use for cancer patients going back 30 years....and why their use has been drastically curtailed in the last decade.

en

00:18:56

Cyclophosphamide

OncoPharm ·

2018/11/15

Discussing one of the main workhorse #oncopharm agents: cyclophosphamide. Topics include is bioactivation, myriad of uses, toxicity (hemorrhagic cystits) prevention and management.

en

00:24:13

Lorlatinib

OncoPharm ·

2018/11/06

Reviewing the latest TKI approved for ALK rearranged metastatic NSCLC. And hey, how 'bout that crazy rifampin hepatotoxicity interaction?

en

00:20:48

October '18 Updates

OncoPharm ·

2018/11/01

Running through recent notable updates on pembrolizumab, olaparib, atezolizumab, palbociclib and 5F9's introduction.

en

00:10:51

Flu Vaccine Use with Immunotherapy

OncoPharm ·

2018/10/25

Discussing the scant evidence regarding influenza vaccination in cancer patients receiving immunotherapy. Warning! - unpublished abstracts are discussed by a guy with laryngitis.

en

00:14:06

Talazoparib

OncoPharm ·

2018/10/18

Another new #oncopharm agent was approved. We talk about talazoparib and how it compares to olaparib for germline BRCA-mutated breast cancer.

en

00:16:06

P1: Tamoxifen for Breast Cancer Risk Reduction

OncoPharm ·

2018/10/11

The Landmarks in Oncology Pharmacy series returns with the P1 study. We review this landmark paper paving the way for breast cancer risk reduction (or chemoprevention) and discuss the mark or lack thereof (frown emoji) it has made in clinical practice.

en

00:27:47

Dacomitinib, cemiplimab & #oncopharm updates

OncoPharm ·

2018/10/04

Dacomitinib & cemiplimab's respective FDA-approvals are discussed followed by a lightning-round review of 4 immunotherapy studies from the last week. We end with dosing updates for 2 multiple myeloma drugs.

en

424 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter